利拉鲁肽而非达格列净或阿卡波糖可增强2型糖尿病患者受损的嗅觉神经激活与认知能力:一项16周随机平行对照研究
研究将36例二甲双胍单药控制不佳的2型糖尿病患者随机分入利拉鲁肽、达格列净或阿卡波糖治疗16周,评估脑功能MRI和认知。利拉鲁肽显著改善左侧海马嗅觉激活及延迟记忆、注意力和执行功能(均P<0.05),达格列净或阿卡波糖无此效果。结构方程模型显示改善部分归因于利拉鲁肽对左侧海马激活(β=0.330,P=0.022)和延迟记忆(β=0.410,P=0.004)的直接效应及代谢改善。
要点
- 利拉鲁肽治疗16周显著增强2型糖尿病患者受损的左侧海马嗅觉激活。
- 利拉鲁肽改善延迟记忆、注意力和执行功能(均P<0.05),达格列净或阿卡波糖无此效果。
- 改善部分归因于利拉鲁肽对左侧海马激活(β=0.330,P=0.022)和延迟记忆(β=0.410,P=0.004)的直接效应及代谢改善。
核心结论
- 头对头研究显示利拉鲁肽增强2型糖尿病患者受损的脑激活并恢复受损认知域,而达格列净和阿卡波糖无此效果。
- 结果扩展了利拉鲁肽的临床应用,并为糖尿病合并高认知衰退风险个体提供了新治疗策略。
研究设计与样本
- 36例二甲双胍单药控制不佳的2型糖尿病患者随机接受利拉鲁肽、达格列净或阿卡波糖治疗16周。
- 所有受试者在干预前后进行脑功能MRI扫描和一组认知评估。
主要发现
- 利拉鲁肽治疗16周显著增强受损的气味诱导左侧海马激活(高斯随机场校正),并改善延迟记忆、注意力和执行功能(均P<0.05),达格列净或阿卡波糖无此效果。
- 结构方程模型分析显示,脑健康和认知功能的改善部分归因于利拉鲁肽对左侧海马激活(β=0.330,P=0.022)和延迟记忆(β=0.410,P=0.004)的直接效应,以及腰围减少、体脂率降低和空腹胰岛素升高的代谢改善(均P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The comparative neuroprotective effects of different antidiabetes drugs have not been characterized in randomized controlled trials. Here, we investigated the therapeutic effects of liraglutide, dapagliflozin, or acarbose treatment on brain functional alterations and cognitive changes in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Thirty-six patients with type 2 diabetes inadequately controlled with metformin monotherapy were randomized to receive liraglutide, dapagliflozin, or acarbose treatment for 16 weeks. Brain functional MRI (fMRI) scan and a battery of cognitive assessments were evaluated pre- and postintervention in all subjects. RESULTS: The 16-week treatment with liraglutide significantly enhanced the impaired odor-induced left hippocampal activation with Gaussian random field correction and improved cognitive subdomains of delayed memory, attention, and executive function (all P < 0.05), whereas dapagliflozin or acarbose did not. Structural equation modeling analysis demonstrated that such improvements of brain health and cognitive function could be partly ascribed to a direct effect of liraglutide on left hippocampal activation (β = 0.330, P = 0.022) and delayed memory (β = 0.410, P = 0.004) as well as to the metabolic ameliorations of reduced waist circumference, decreased body fat ratio, and elevated fasting insulin (all P < 0.05). CONCLUSIONS: Our head-to-head study demonstrated that liraglutide enhanced impaired brain activation and restored impaired cognitive domains in patients with type 2 diabetes, whereas dapagliflozin and acarbose did not. The results expand the clinical application of liraglutide and provide a novel treatment strategy for individuals with diabetes and a high risk of cognitive decline.
引用
- Cheng H, Zhang Z, Zhang B, et al. Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study. Diabetes Care. 2022. PMID: 35263425. doi:10.2337/dc21-2064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。